2002 issue 2


Volume 18, issue 2


Koszty powtórnego udaru mózgu w Polsce

Maciej Niewada1, Bogumił Kamiński1, Adam Kobayashi1, Anna Członkowska1, Andrzej Członkowski1
1. Katedra Farmakologii Doświadczalnej i Klinicznej Akademii Medycznej w Warszawie; I Klinika Neurologiczna Instytutu Psychiatrii i Neurologii w Warszawie; Katedra Wspomagania Podejmowania Decyzji Instytutu Ekonometrii Szkoły Głównej Handlowej
Farmakoterapia w Psychiatrii i Neurologii, 2002, 2, 191-203


The high risk of stroke recurrence can be reduced with effective prevention healthcare programs. 2nd Neurological Department clinical database was reviewed and 105 secondary stroke patients evaluated. Survivors were surveyed on healthcare resources consumption within previous year and indirect costs including care time at home and the employment status. Life expectancy was estimated using Kaplan-Meier method along with parametrical hazard function estimator. Average total cost and its 95% bootstrap confidence interval were calculated. Eventually survey was aimed at evaluating patients disability with Barthel ADL Index and it's relation to the total costs of secondary stroke was determined.
Life expectancy for Polish secondary stroke patient was found to be 3.9 years (95% CI: 2.25; 5.71). Average lifetime secondary stroke costs totaled 52181 USD (95% CI: 43536; 61602 (PPP'2000). The direct costs were estimated at 24099 USD and morbidity productivity loss amounted to 34.3%. It was found that total cost decreased as ADL increased.
In Poland indirect costs determine the substantial costs of secondary stroke. Effective secondary prevention can produce clinical benefits and economic savings resulting from limiting the burden of secondary stroke.